173010-13-4

Upstream product

• 172958-85-9 (1'S)-(3'R)-2-(3'-hydroxy-2',2'-dimethyl-6'-methylene-cyclohexyl)-ethyl acetate 
• 2270-59-9 1-bromo-4-methylpent-3-ene 
• 67985-68-6 (4'S)-2-(2',2',5',5'-tetramethyl-<1',3'>dioxolan-4'-yl)-ethanol 
• 106777-49-5 (3S)-5-Brom-2,3-isopropylidendioxy-2-methylpentan 
• 172958-94-0 (3Z)-(4'S)-6-(2',2',5',5'-tetramethyl-<1',3'>dioxolan-4'-yl)-4-trimethylsilanylmethyl-hex-3-en-1-yl acetate 
• 172958-86-0 Acetic acid (Z)-6-((R)-3,3-dimethyl-oxiranyl)-4-trimethylsilanylmethyl-hex-3-enyl ester 
• 172958-97-3 (3Z)-(7S)-7,8-dihydroxy-8-methyl-4-trimethylsilanylmethyl-non-3-en-1-yl acetate 
• 172958-88-2 (5S)-5-<2'-(4'',5''-dihydrofuran-2''-yl)ethyl>-2,2,4,4-tetramethyl-<1,3>-dioxolane 
• 172958-99-5 tert-butyl-dimethyl-[2-((S)-2,2,5,5-tetramethyl-[1,3]dioxolan-4-yl)-ethoxy]-silane 
• 172958-92-8 (5S)-5-(2'-t-butyldimethylsilyloxy)-2-methyl-pentane-2,3-diol 
• 172958-89-3 (5S)-5-(2'-iodoethyl)-2,2,4,4-tetramethyl-<1,3>dioxolane 
• 172958-93-9 (5S)-5-bromo-2-methyl-pentane-2,3-diol 
• 183728-39-4 (1'S,3'R)-2-(3'-hydroxy-2',2'-dimethyl-6'-methylene-cyclohexyl)-ethyl trimethylacetate 

Downstream Products

• 184046-12-6 (1''R)-(1'E)-2-[2'-(2'',2''-dimethyl-6''-methylene-cyclohexyl)-ethylidene]-butane-1,4-diol 
• 172958-84-8 (1''R)-(1'E)-3-<2'-(2'',2''-dimethyl-6''-methylene-cyclohexyl)-ethylidene>-dihydrofuran-2-one 
• 173010-14-5 (1'R)-(2',2'-dimethyl-6'-methylene-cyclohexyl)-acetaldehyde 

Relevant academic research and scientific papers

Enantioselective synthesis of γ-cyclohomocitral, pallescensone, and ancistrodial

A simple and efficient enantioselective synthesis of γ-cyclohomocitral, a key and versatile intermediate for the synthesis of some monocyclofarnesane terpenoids, is described. This features a highly sitoselective Sharpless asymmetric dihydroxylation of a

Saponaceolides: Differential cytotoxicity and enantioselective synthesis of the right-hand lactone moiety

The enantioselective synthesis of the right-hand lactone moiety 5 of saponaceolide B, 2, is described. The mean graph profiles of 5 do not match the characteristic patterns of differential cytotoxicity of saponaceolides A, 1, and B, 2, in the NC1 human disease-oriented tumor screening panel, pointing out the need of the entire saponaceolide structure for maintaining the specificity and potency of the antitumor activity. En route to 5 several useful chiral building blocks, such as compounds 6, 10, 19, 27, and 28 were prepared.